I'm LongbridgeAI, I can summarize articles.During Tuesday's intraday session, several healthcare stocks experienced significant volatility. Top gainers included SCWorx (WORX) up 42.9%, Myriad Genetics (MYGN) up 36.85%, and Anbio Biotechnology (NNNN) up 22.32%. Conversely, major losers featured China SXT Pharmaceuticals (SXTC), which plummeted 41.5%, followed by CDT Equity (CDT) down 14.04% and Bristol-Myers Squibb Celegne Contingent Value Rights (CELGR) declining 10.01%.
Gainers
- SCWorx (NASDAQ:WORX) stock moved upwards by 42.9% to $3.83 during Tuesday's regular session.
- Myriad Genetics (NASDAQ:MYGN) shares moved upwards by 36.85% to $5.76. The company's market cap stands at $397.6 million.
- Anbio Biotechnology (NASDAQ:NNNN) stock increased by 22.32% to $4.0. The company's market cap stands at $143.5 million.
- Clene (NASDAQ:CLNN) shares moved upwards by 20.66% to $3.97. The market value of their outstanding shares is at $46.7 million.
- Concord Medical Services (NYSE:CCM) stock increased by 17.69% to $4.19. The company's market cap stands at $15.4 million.
- iBio (NASDAQ:IBIO) stock rose 17.08% to $0.89. The company's market cap stands at $48.8 million.
Losers
- China SXT Pharmaceuticals (NASDAQ:SXTC) stock fell 41.5% to $0.07 during Tuesday's regular session.
- CDT Equity (NASDAQ:CDT) shares decreased by 14.04% to $0.16.
- Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock declined by 10.01% to $0.1.
- NexGel (NASDAQ:NXGL) shares declined by 9.83% to $5.23. The market value of their outstanding shares is at $2.8 million.
- DarioHealth (NASDAQ:DRIO) shares declined by 9.8% to $4.05. The market value of their outstanding shares is at $43.9 million.
- BioVie (NASDAQ:BIVI) stock decreased by 8.4% to $1.25. The company's market cap stands at $11.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to unlock757characters for free
Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.